Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loncastuximab tesirine - ADC Therapeutics

Next Previous
Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Anti-CD19-PBD-conjugate-ADC; Lonca; Lonca-T; loncastuximab tesirine-lpyl; MT-2111; ZYNLONTA

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics; Spirogen
  • Developer ADC Therapeutics; Mitsubishi Tanabe Pharma Corporation; Swedish Orphan Biovitrum
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Preregistration B-cell lymphoma
  • Phase II Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Mantle-cell lymphoma
  • Phase I Non-Hodgkin's lymphoma
  • Discontinued Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 16 Jun 2025 Efficacy data from a phase II trial in Marginal zone B-cell lymphoma released by ADC Therapeutics
  • 12 Jun 2025 Updated efficacy and adverse events data from a phase I LOTIS-7 trial in Non-Hodgkin's lymphoma released by ADC Therapeutics
  • 07 Jan 2025 ADC Therapeutics terminates a phase II LOTIS-9 trial in Diffuse large B cell lymphoma (Combination therapy, First-line therapy, In the elderly) in USA (IV), as benefit-risk profile does not support continuation (NCT05144009)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top